Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 2 (2024)

Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry

  • Sofie Brouwers
  • Raphael Heimgartner
  • Natallia Laptseva
  • Adriano Aguzzi
  • Niklas F. Ehl
  • Thomas Fehr
  • Felicitas Hitz
  • Hans H. Jung
  • Joel Kälin
  • Markus G. Manz
  • Beat Müllhaupt
  • Frank Ruschitzka
  • Harald Seeger
  • Georg Stussi
  • Markus Zweier
  • Andreas J. Flammer
  • Bernhard Gerber
  • Rahel Schwotzer
DOI
https://doi.org/10.57187/s.3485
Cite this as:
Swiss Med Wkly. 2024;154:3485
Published
15.02.2024

Summary

AIMS OF THE STUDY: Systemic amyloidoses are rare protein-folding diseases with heterogeneous, often nonspecific clinical presentations. To better understand systemic amyloidoses and to apply state-of-the-art diagnostic pathways and treatment, the interdisciplinary Amyloidosis Network was founded in 2013 at University Hospital Zurich. In this respect, a registry was implemented to study the characteristics and life expectancy of patients with amyloidosis within the area covered by the network. Patient data were collected retrospectively for the period 2005–2014 and prospectively from 2015 onwards.

METHODS: Patients aged 18 years or older diagnosed with any subtype of systemic amyloidosis were eligible for inclusion if they were treated in one of the four referring centres (Zurich, Chur, St Gallen, Bellinzona). Baseline data were captured at the time of diagnosis. Follow-up data were assessed half-yearly for the first two years, then annually.

RESULTS: Between January 2005 and March 2020, 247 patients were screened, and 155 patients with confirmed systemic amyloidosis were included in the present analysis. The most common amyloidosis type was light-chain (49.7%, n = 77), followed by transthyretin amyloidosis (40%, n = 62) and amyloid A amyloidosis (5.2%, n = 8). Most patients (61.9%, n = 96) presented with multiorgan involvement. Nevertheless, single organ involvement was seen in all types of amyloidosis, most commonly in amyloid A amyloidosis (75%, n = 6).

The median observation time of the surviving patients was calculated by the reverse Kaplan-Meier method and was 3.29 years (95% confidence interval [CI] 2.33–4.87); it was 4.87 years (95% CI 3.14–7.22) in light-chain amyloidosis patients and 1.85 years (95% CI 1.48–3.66) in transthyretin amyloidosis patients, respectively. The 1-, 3- and 5-year survival rates were 87.0% (95% CI 79.4–95.3%), 68.5% (95% CI 57.4–81.7%) and 66.0% (95% CI 54.6–79.9%) respectively for light-chain amyloidosis patients and 91.2% (95% CI 83.2–99.8%), 77.0% (95% CI 63.4–93.7%) and 50.6% (95% CI 31.8–80.3%) respectively for transthyretin amyloidosis patients. There was no significant difference between the two groups (p = 0.81).

CONCLUSION: During registry set-up, a more comprehensive work-up of our patients suffering mainly from light-chain amyloidosis and transthyretin amyloidosis was implemented. Survival rates were remarkably high and similar between light-chain amyloidosis and transthyretin amyloidosis, a finding which was noted in similar historic registries of international centres. However, further studies are needed to depict morbidity and mortality as the amyloidosis landscape is changing rapidly.

References

  1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug;349(6):583–96. 10.1056/NEJMra023144 DOI: https://doi.org/10.1056/NEJMra023144
  2. Nuvolone M, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant. 2017 May;32(5):770–80. DOI: https://doi.org/10.1093/ndt/gfw305
  3. Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016 Dec;23(4):209–13. 10.1080/13506129.2016.1257986 DOI: https://doi.org/10.1080/13506129.2016.1257986
  4. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv. Ther; 2015. DOI: https://doi.org/10.1016/j.cardfail.2015.06.203
  5. Ritts AJ, Cornell RF, Swiger K, Singh J, Goodman S, Lenihan DJ. Current Concepts of Cardiac Amyloidosis: Diagnosis, Clinical Management, and the Need for Collaboration. Heart Fail Clin. 2017 Apr;13(2):409–16. 10.1016/j.hfc.2016.12.003 DOI: https://doi.org/10.1016/j.hfc.2016.12.003
  6. Pop B, Fetica B, Blaga ML, Trifa AP, Achimas-Cadariu P, Vlad CI, et al. The role of medical registries, potential applications and limitations. Med Pharm Rep. 2019 Jan;92(1):7–14. 10.15386/cjmed-1015 DOI: https://doi.org/10.15386/cjmed-1015
  7. Gertz MA, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10thInternational Symposium on Amyloid and Amyloidosis. in American Journal of Hematology, 2005. DOI: https://doi.org/10.1002/ajh.20381
  8. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016 Jun;133(24):2404–12. 10.1161/CIRCULATIONAHA.116.021612 DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.021612
  9. Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012 Jan;119(2):488–93. 10.1182/blood-2011-06-358507 DOI: https://doi.org/10.1182/blood-2011-06-358507
  10. Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012 Feb;119(8):1844–7. 10.1182/blood-2011-07-365510 DOI: https://doi.org/10.1182/blood-2011-07-365510
  11. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar;30(9):989–95. 10.1200/JCO.2011.38.5724 DOI: https://doi.org/10.1200/JCO.2011.38.5724
  12. Gillespie BW, Chen Q, Reichert H, Franzblau A, Hedgeman E, Lepkowski J, et al. Estimating population distributions when some data are below a limit of detection by using a reverse Kaplan-Meier estimator. Epidemiology. 2010 Jul;21(4 Suppl 4):S64–70. 10.1097/EDE.0b013e3181ce9f08 DOI: https://doi.org/10.1097/EDE.0b013e3181ce9f08
  13. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018 Aug;39(30):2799–806. 10.1093/eurheartj/ehx589 DOI: https://doi.org/10.1093/eurheartj/ehx589
  14. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016 Jun;387(10038):2641–54. 10.1016/S0140-6736(15)01274-X DOI: https://doi.org/10.1016/S0140-6736(15)01274-X
  15. Spezialitätenliste (SL) - Präparate. Online. Available: https://www.spezialitaetenliste.ch/ShowPreparations.aspx. Accessed: 13-Feb-2023.
  16. Y. Rauf, et al. Real World Experience of Tc-DPD scintigraphy as a diagnostic imaging tool in amyloidosis. 2022.
  17. M. Zampieri et al., Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. Int. J. Cardiol., vol. 335, 2021. DOI: https://doi.org/10.1016/j.ijcard.2021.04.023
  18. Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and Survival Trends in Amyloidosis, 1987-2019. N Engl J Med. 2020 Apr;382(16):1567–8. 10.1056/NEJMc1917321 DOI: https://doi.org/10.1056/NEJMc1917321
  19. Condoluci A, Théaudin M, Schwotzer R, Pazhenkottil AP, Arosio P, Averaimo M, et al. Management of transthyretin amyloidosis. Swiss Med Wkly. 2021 Oct;151(4142):w30053. 10.4414/smw.2021.w30053 10.4414/SMW.2021.w30053 DOI: https://doi.org/10.4414/SMW.2021.w30053
  20. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013 Dec;31(34):4319–24. 10.1200/JCO.2013.50.8499 DOI: https://doi.org/10.1200/JCO.2013.50.8499
  21. Dittus C, Uwumugambi N, Sun F, Sloan JM, Sanchorawala V. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Sep;22(9):1729–32. 10.1016/j.bbmt.2016.05.027 DOI: https://doi.org/10.1016/j.bbmt.2016.05.027
  22. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003 May;107(19):2440–5. 10.1161/01.CIR.0000068314.02595.B2 DOI: https://doi.org/10.1161/01.CIR.0000068314.02595.B2
  23. Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN. Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica. 2011 Jul;96(7):1079–80. 10.3324/haematol.2011.040493 DOI: https://doi.org/10.3324/haematol.2011.040493
  24. Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018 Mar;10(1):e2018022. 10.4084/mjhid.2018.022 DOI: https://doi.org/10.4084/mjhid.2018.022
  25. Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid. 2017 Sep;24(3):162–6. 10.1080/13506129.2017.1342235 DOI: https://doi.org/10.1080/13506129.2017.1342235
  26. Immonen K, Finne P, Grönhagen-Riska C, Pettersson T, Klaukka T, Kautiainen H, et al. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland. Amyloid. 2011 Mar;18(1):25–8. 10.3109/13506129.2010.549252 DOI: https://doi.org/10.3109/13506129.2010.549252
  27. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019 Jul;140(1):16–26. 10.1161/CIRCULATIONAHA.118.038169 DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.038169
  28. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al.; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep;379(11):1007–16. 10.1056/NEJMoa1805689 DOI: https://doi.org/10.1056/NEJMoa1805689
  29. D. Adams and S. Ole, Patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis: Results from the phase 3 APOLLO study. Rev. Neurol. (Paris)., 2018. DOI: https://doi.org/10.1016/j.neurol.2018.01.085
  30. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul;379(1):22–31. 10.1056/NEJMoa1716793
  31. Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, et al. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020 Dec;150(4950):w20364. 10.4414/smw.2020.20364 DOI: https://doi.org/10.4414/smw.2020.20364

Most read articles by the same author(s)

1 2 3 4 5 6 > >>